1. Six first-line tyrosine kinase inhibitors reveal novel inhibition potential for the EGFR S768I mutation.
- Author
-
Wang, Ying, Liu, Qian, Chu, Chunhong, Li, Lanxin, Wang, Zhenxing, Liu, Qiyu, Wu, Guangyao, Wei, Xiangkai, An, Lei, and Ma, Jiguang
- Subjects
- *
PROTEIN-tyrosine kinase inhibitors , *EPIDERMAL growth factor receptors , *NON-small-cell lung carcinoma , *WESTERN immunoblotting - Abstract
Lung cancer, the leading cause of cancer-related mortality, is the most commonly diagnosed cancer. Tyrosine kinase inhibitors (TKIs) are considered a drug-targeted therapy for non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, limited data are available involving the activity of EGFR TKIs against rare EGFR mutations. Here, based on an endogenous EGFR-depleted cell Line H3255 by CRISPR, H3255 cells with rare mutant EGFRS768I and compound mutations EGFRS768I+L858R were tested using cell proliferation assay, cytotoxicity, membrane potential, flow cytometry and Western blot analysis. We conducted cytotoxicity screening of EGFR mutations on six front-line TKIs based on first-, second-, and third-generation TKIs (afatinib, dacomitinib, osimertinib, erlotinib, gefitinib, and icotinib). The results showed that the sensitivity of these mutants containing rare variants EGFRS768I to six front-line TKIs was enriched in the irreversible TKI cytotoxicity assays by determining their change in cytotoxicity, apoptosis, cell proliferation and signal pathway factors. Importantly, the variants harboring EGFRL858R (H3255), EGFRS768I (H3255S768I) and EGFRS768I+L858R (H3255S768I+L858R) were sensitive to six TKIs and induced cytotoxicity through different pathways. Moreover, the compound mutations EGFRS768I+L858R showed more TKI resistance than EGFRS768I mutation and EGFRL858R mutation. We present a comprehensive reference for the sensitivity of EGFRS768I variants to six front-line TKIs. For patients with the EGFR S768I mutation and compound mutations EGFRS768I+L858R, six first-line TKIs appear to be reasonable therapeutic options. • The EGFR S768I variants were constructed using the CRISPR method. • Six first-line TKIs induced cytotoxicity of EGFR S768I mutation. • The patients with EGFR S768I mutation are more likely to benefit from six first-line TKIs. • Icotinib and Erlotinib appears to be reasonable therapeutic option for activing multiple signal pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF